Changes in serum and red blood cell membrane lipids in patients treated with interferon ribavirin for chronic hepatitis C

One of the side effects by interferon ribavirin (I/R) treatment is haemolytic anemia, causing some patients to discontinue I/R treatment. The exact mechanism of I/R-induced anemia is unknown. The aim of this study is to evaluate the effects of I/R treatment on the serum lipid and red blood cell (RBC...

Full description

Saved in:
Bibliographic Details
Published inClinical and experimental medicine Vol. 5; no. 4; pp. 190 - 195
Main Authors Tanaka, H, Miyano, M, Ueda, H, Fukui, K, Ichinose, M
Format Journal Article
LanguageEnglish
Published Italy Springer Nature B.V 01.12.2005
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:One of the side effects by interferon ribavirin (I/R) treatment is haemolytic anemia, causing some patients to discontinue I/R treatment. The exact mechanism of I/R-induced anemia is unknown. The aim of this study is to evaluate the effects of I/R treatment on the serum lipid and red blood cell (RBC) membrane lipid profiles of patients with chronic hepatitis C (CHC) and the association between changes of RBC membrane lipids and haemolytic anemia by I/R treatment. Fourteen patients with CHC were treated with I/R and their serum lipid profiles were studied. In addition, in seven of the 14 patients, the RBC membrane lipid profiles were analysed. In the RBC membrane lipid composition, the total cholesterol, total phospholipids and cholesterol/phospholipids (C/PL) ratio were significantly increased. Phosphatidylcholine (PC) and the phosphatidylcholine/ sphingomyelin (PC/SM) ratio were significantly decreased and other phospholipid fractions were significantly increased. Changes in the serum lipids and RBC membrane lipid profiles of patients with CHC treated with I/R were shown. Especially, a decrease in the RBC deformability and membrane fluidity by changes in these RBC membrane lipids was supposed and it is suggested that those changes may result in haemolytic anemia by I/R treatment.
ISSN:1591-8890
1591-9528
DOI:10.1007/s10238-005-0085-0